Differential phosphorylation of CXCR4 and CXCR7
Early stage researcher 10 (ESR10) project – Aurelien Zarca
Supervision: Prof MJ Smit, Dr M Siderius, Dr H Vischer, Prof R Leurs
Host: VU (NL) – VU University Amsterdam, Dept. of Medicinal Chemistry
I- Project proposal:
Aim:
1. Delineate ligand (in)dependent CXCR4 and CXCR7 phosphorylation profiles.
2. Determine kinases involved in CXCR4 and CXCR7 phosphorylation.
3. Define functional consequences of differential CXCR4 and CXCR7 phosphorylation in distinct cancer cell types.
Methodology:
To study the role of CXCR4 and CXCR7 phosphorylation, receptor mutants and phosphospecific antibodies will be used and/or generated. To identify the kinases involved FRET/BRET and gene silencing experiments will be performed. The functional consequences of differential phosphorylation in various cancer cell lines will be explored by focussing on receptor desensitization/trafficking using confocal fluorescence microscopy and automated high content screening and signalling to multiple intracellular pathways (bias).
Planned secondments: arGEN-X (BE), UWUE (DE), Vivia Biosystems (ES)
II- Requirement candidate:
Required diploma: MSc degree in molecular/biomedical Life Sciences, Pharmaceutical Sciences or related Life Science degree.
Required expertise: cell culture, cell-based assays, biochemistry, molecular biology. Recommended expertise: GPCR molecular pharmacology, chemokine biology, imaging, FRET/BRET based signalling, radioligand binding, oncogenic assays.
Key publications:
1. Maussang D, et al, Smit MJ (2013) Llama-derived single variable domains (Nanobodies) directed against CXCR7 reduce head and neck cancer cell growth in vivo. J Biol Chem 288: 29562-72.
2. Canals M, Scholten DJ, de Munnik S, Han MK, Smit MJ, Leurs R (2012) Ubiquitination of CXCR7 controls receptor trafficking. PLoS One. 7:e34192.
3. Watts AO, Verkaar F, van der Lee MM, Timmerman CA, Kuijer M, van Offenbeek J, van Lith LH, Smit MJ, Leurs R, Zaman GJ, Vischer HF (2013) β-Arrestin recruitment and G protein signaling by the atypical human chemokine decoy receptor CCX-CKR. J Biol Chem 288:7169-81.
4. Jähnichen S et al Smit MJ (2010) CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci USA. 107: 20565.
Follow us on
My project will be focused on the role of #CXCR4/ACKR3/GRK2 -governed networks in cancer cell migration and metastasis.
New review on #gpcr structural dynamics out in COSB. Great teamwork with the @JanaSelent group. Thanks to @Lundbeckfonden and @novonordiskfond https://lnkd.in/eyjrA5V
A reminder that applications for our new Deputy Editor in Chief of #PharmacologyMatters close on Monday. https://buff.ly/2PNWf4V
ONCORNET2.0 is the successor to #ONCORNET. You can see some of the work of ESRs from the first ONCORNET in this special issue of @MolPharmJournal from 2019, with reviews on #CXCR4 and #ACKR3 structure and function: https://molpharm.aspetjournals.org/content/96/6
Hi everyone – we’re on Twitter! ONCORNET2.0 is a #MarieCurie ITN of 16 ESRs across Europe studying #chemokine #GPCRs #CXCR4 and #ACKR3 in cancer. Our projects cover molecular dynamics, medchem, #pharmacology through to translational work. Follow us for updates from our ESRs!
Contact details
Please contact us at:
info@oncornet.eu
ONCORNET Coordinator
VU University Amsterdam
The Netherlands